WakeMed Children’s Endocrinology and Diabetes is involved in many different types of diabetes and research projects. Below are brief descriptions of the current studies. To learn more, please call our research coordinator at 919-862-1200.
Type 1 Diabetes: TrialNet
Do you have a family member with Type 1 diabetes?
If the answer is “yes”, then you and your family may have a unique opportunity to join in the fight against diabetes. Researchers from The University of Florida and WakeMed Children’s Endocrinology & Diabetes, in collaboration with the National Institutes of Health and Clinical Centers across the country, are seeking a better understanding of how Type 1 diabetes develops. TrialNet researchers are also searching for ways to both prevent and quickly intervene medically in those newly diagnosed with the disease.
For TrialNet’s Natural History Study, researchers are seeking to test family members of people with Type 1 diabetes to determine if these family members show signs of developing the disease.
The clinic is also engaged in other TrialNet sponsored studies
To learn more about TrialNet, go to their website www.diabetestrialnet.org or call our research coordinator at 919-862-1200.
Type 2 Diabetes: WELKid DM Study
With the growing number of children and adolescents developing Type 2 diabetes, there is a need for alternative treatment options. Welchol (colesevelam) is a medication that is currently FDA approved to treat high cholesterol in both children and adults. Recently it was found to improve blood sugars in adults with Type 2 diabetes, and has been approved to treat Type 2 diabetes in adults. The WELKid DM study is looking at the safety and effectiveness of Welchol (colesevelam) as a treatment for children and adolescents with Type 2 diabetes.
To learn more about the WELKid DM Study, call our research coordinator at 919-862-1200.
Growth Hormone: ANSWER
Is your child currently on Norditropin?
If the answer is “yes”, your child may qualify to participate in this long-term study. ANSWER is a multi-national database that anonymously collects patient information that will provide data about growth hormone safety, efficacy, dosing requirements, and secondary benefits. This study is only for patients currently on Norditropin (your child can participate even if they have previously been on a different brand of growth hormone).
To learn more about ANSWER, call our research coordinator at 919-862-1200.